Company intelligence / Profile preview

LongevityBank

Malaysia

Ownership: Private
Development stage: Other

Overview

LongevityBank, a platform under CytoMed Therapeutics, focuses on developing autologous cord blood-derived NK and T cell therapies for autoimmune diseases and cancers. It leverages its proprietary cord blood banking and expansion capabilities, enabled by a licensed cord blood bank in Malaysia. Successful expansion of clinical-scale natural killer (NK) cells from cryopreserved cord blood has been demonstrated, supporting platform development for scalable therapeutics. This autologous therapy platform complements CytoMed’s allogeneic therapy pipeline.

Therapeutic areas: OncologyImmunology
Modalities: NK cell therapyT cell therapyStem cell therapyCell therapy
Industry: Biotech

Beyond the preview

Go deeper on LongevityBank.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on LongevityBank.

Explore the full profile